| 货号 | AF3246-SP |
| 别名 | ECI; ECIMUM; Endogenous carboxypeptidase inhibitor; latexin; LXN; TCI; TCIProtein MUM; Tissue carboxypeptidase inhibitor |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) Immunoprecipitation(25 µg/mL) |
| 目标/特异性 | Detects human Latexin in direct ELISAs and Western blots. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunoprecipitation: 25 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 56925 (Human); 17035 (Mouse); 59073 (Rat) |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | E. coli-derived recombinant human Latexin Glu2-Glu222 Accession # AAH05346 |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Human Latexin, also known as tissue carboxypeptidase inhibitor, is the only mammalian carboxypeptidase inhibitor identified so far. Latexin was initially identified as a marker of neurons in the lateral neocortex of the developing brain (hence latexin) (1). Further studies have shown that latexin is highly expressed in mast cells and macrophages (2, 3). It is induced in acute pancreatitis and lung inflammatory disease. In addition, it is able to inhibit carboxypeptidases from the pancreas (CPA1 and CPA2) and mast cells (CPA3) (4). Therefore, it is thought that latexin primarily functions in inflammation and innate immunity pathways. Compared to other carboxypeptidase inhibitors from plants and parasites, the 222 amino acid latexin is much larger and more importantly, it lacks some conserved C-terminal residues, which interact with the target carboxypeptidase in a substrate-like manner (5). This distinct feature of latexin suggests that it has a different carboxypeptidase inhibition mechanism. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|